Takeda offloaded cancer assets, AstraZeneca formed drug discovery JV in China, Biocon's Herceptin biosimilar plant cleared FDA.
German regulators have signed off on a corrective and preventive action plan for one of Dr. Reddy’s formulation production facilities in India.
There’s no stopping time…but these Patient Recruitment & Retention tactics can help overcome trial delays. Our global late-stage study expert discusses…
Indian drugmaker Dr. Reddy’s said it has been named in a securities class-action lawsuit in the U.S. for alleged violation of federal securities laws.
Russian biotech Biocad said it reached a deal with Sothema Labs of Morocco to produce biosimilars rituximab and bevacizumab, used to treat cancer.
With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.
Gilead is introducing Sovaldi in China, where it faces mounting competitive pressure, at a steep discount.
Biocon has resolved FDA concerns about a plant in India, setting it and Mylan up to potentially win FDA approval for the first Herceptin biosimilar.
Pfizer exits a JV with China's Hisun Pharma, FDA approved the first digital medicine, and Astellas was added to a charity donation probe.
Astellas has joined the biopharma who's who of companies to disclose federal scrutiny for donations to charities that help patients cover drug costs.
Lupin has been trying for two years to bring its plant in Goa, India, up to FDA standards, but a new warning letter says more improvements are needed.